Unknown

Dataset Information

0

Tumor-infiltrating CD8+ T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited-stage small cell esophageal carcinoma.

ABSTRACT:

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC8236121 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer.
| S-EPMC5873899 | biostudies-literature
Unknown Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
| S-EPMC6744628 | biostudies-literature
Unknown Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.
| S-EPMC5414863 | biostudies-literature
Unknown m<sup>6</sup>A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer.
| S-EPMC8607595 | biostudies-literature
Unknown Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1<sup>+</sup> CD8<sup>+</sup> and CD8<sup>+</sup> T cells as predictive of response to neoadjuvant chemotherapy in breast cancer.
| S-EPMC7529566 | biostudies-literature
Unknown Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
| S-EPMC8637339 | biostudies-literature
Unknown The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma.
| S-EPMC7790855 | biostudies-literature
Unknown Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
| S-EPMC7156837 | biostudies-literature
Unknown Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
| S-EPMC2700346 | biostudies-literature
Unknown Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.
| S-EPMC6040635 | biostudies-literature